general talk, page-316

if by treatment you mean our clinical arm only of the company they pretty much break even / maybe a small profit soon.

if you mean the whole company including its core drug development goals then remember we are bio and it won't be for many years. (trials are costly).

we only need a small number of clinics to capture RWD. e.g the cannabis clinics are now well over 10,000+ patients over few years small number of clinics. same play book for psyc clinics

While RX5 is stalled due to limited capital. RWD capture continues through the clinical, we are a drug developer / bio making revenue without an approved product. (unheard of and good strategy)

and RX7/9 while slow continue in a good capital structure in that it costs us nothing as NIH is currently covering all costs and we get all the benefit and get to fully keep IP and ownership.

company rolling along not bad.

the next quarterly report might get some people interested when revenue from the new psych clinic comes onto the books.